NGO-provided free HIV treatment and services in Burkina Faso: Scarcity, therapeutic rationality and unfair process

International Journal for Equity in Health

Volumn 11, Issue 1, 2012, Pages

  Ridde, Valéry ^a,b,c   Somé, Paul Andre ^d   Pirkle, Catherine M ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^d Independent Consultant ^*  (Burkina Faso)

Author keywords

Access; Antiretrovirals; Selection processes; User fees; West Africa

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; ANTIRETROVIRUS AGENT;

DISEASE TREATMENT; FINANCIAL SERVICES; HEALTH EXPENDITURE; HEALTH SERVICES; HEALTH WORKER; HUMAN IMMUNODEFICIENCY VIRUS; NONGOVERNMENTAL ORGANIZATION; PUBLIC ACCESS; QUALITATIVE ANALYSIS;

ANTIVIRAL THERAPY; ARTICLE; BURKINA FASO; DRUG COST; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH DISPARITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; VIRUS LOAD; ADULT; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; INFORMATION PROCESSING; LEGAL ASPECT; MALE; MIDDLE AGED; NATIONAL HEALTH SERVICE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POLICY; STATISTICS;

BURKINA FASO;

ADULT; ANTI-RETROVIRAL AGENTS; BURKINA FASO; FEMALE; FINANCING, GOVERNMENT; FOCUS GROUPS; GOVERNMENT AGENCIES; GUIDELINES AS TOPIC; HEALTH CARE RATIONING; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; ORGANIZATIONAL POLICY; ORGANIZATIONS; QUALITATIVE RESEARCH; STATE MEDICINE;

EID: 84857702851     PISSN: None     EISSN: 14759276     Source Type: Journal    
DOI: 10.1186/1475-9276-11-11     Document Type: Article

References (44)

1. A scoping review of the literature on the abolition of user fees in heathcare services in Africa. Ridde V, Morestin F, Health Policy Plan 2010 26 1 1 11 20547653
2. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries. Souteyrand YP, Collard V, Moatti JP, Grubb I, Guerma T, AIDS 2008 22 Suppl. 1 161 S168 18664948
3. Gratuité des traitements du sida en Afrique: un impératif de santé publique. Taverne B, Population, développement et VIH/Sida et leurs rapports avec la pauvreté ONU. New York: Report presented at the 38th Session of the UN Commission on Population and Development 2005 April 4-8, 2005 22396489
4. Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia. Reniers G, Araya T, Davey G, Nagelkerke N, Berhane Y, Coutinho R, Sanders EJ, AIDS 2009 23 511 518 10.1097/QAD.0b013e32832403d0 19169138
5. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, Ndoye I, AIDS 2003 17 Suppl. 3 103 S108 15080188
6. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, De Kock K, Lancet 2006 368 9534 505 510 10.1016/S0140-6736(06) 69158-7 16890837 (Pubitemid 44142772)
7. Antiretroviral use in Ouagadougou, Burkina Faso. Nguyen V-K, Grennan T, Peschard K, Tan D, Tiendrébéogo I, AIDS 2003 17 Suppl. 3 109 S111 15080191
8. "The problem of the worst-off is dealt with after all other issues": the equity and health policy implementation gap in Burkina Faso. Ridde V, Soc Sci Med 2008 66 1368 1378 10.1016/j.socscimed.2007.10.026 18248864 (Pubitemid 351232101)
9. African Union, Assembly of the African Union Kampala, Uganda: Fifteenth Ordinary Session 25 27 July 2010 2010
10. INSD, Annuaire statistique. dition 2008 INSD: Ouagadougou 2009
11. Analyse comparée des plans stratégiques de lutte contre le VIH en Hati et au Burkina Faso. Foro A, Ridde V, Science et technique, Sciences de la santé, Spécial hors série n°1 2008 75 84
12. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resources country. Kouanda S, Bocoum Yaya F, Doulougou B, Bila B, Yaméogo M, Sanou M, Sawadogo M, Sondo B, Msellati P, Desclaux A, Obermeyer C, AIDS Care 2010 22 9 1146 52 10.1080/09540121003605047 20824567
13. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A, Trop Med Int Health 2010 15 16 33 20586957
14. Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment. Nguyen V-K, Ako CY, Niamba P, Sylla A, Tiendrébéogo I, AIDS 2007 21 Suppl. 5 31 S35 18032936
15. Bocoum Yaya F, La prise en charge des patients infectés par le VIH/SIDA au Burkina Faso: une revue des cots supportés par les patients. Paper presented at the Symposium sur L'accès aux traitements antirétroviraux: leçons des expériences Burkina Faso: Ouagadougou 2008
16. Stakeholders' participation in operational research on HIV care: insights from Burkina Faso. Desclaux A, Kouanda S, Obermeyer CM, AIDS 2010 24 Suppl. 1 79 S85 20023444
17. La place de la participation dans les processus évaluatifs des politiques de lutte contre le VIH au Burkina Faso. Somé P-A, Ridde V, Science et technique, Sciences de la santé, Spécial hors série n° 1 2008 65 73
18. CNLS, Bilan général de la mise en oeuvre du plan national multisectoriel de lutte contre le VIH et les IST (PNM) de l'année 2008 Ouagadougou: CNLS: VIIIème session ordinaire du CNLS-IST 2009
19. Geng E, Muyindike W, Glidden D, Bwana M, Yiannoutsos C, Braitstein P, Musinguzi N, Bangsberg D, Martin J, EA-IeDEA, Failure to initiate ART, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda: understanding engagement in care in resource-limited settings Boston: Conference on Retroviruses and Opportunistic Infections 2011
20. Kohler P, Free CTX substantially improves retention among ART ineligible clients in a Kenyan HIV treatment program Boston: Conference on Retroviruses and Opportunistic Infections 2011
21. Adherence and retention in HIV care in resource limited settings. Smart T, 2011 Aidsmap, editor. London
22. Applying an equity lens to child health and mortality: more of the same is not enough. Victora CG, Wagstaff A, Schellenberg JA, Gwatkin D, Claeson M, Habicht JP, Lancet 2003 362 9379 233 241 10.1016/S0140-6736(03)13917-7 12885488 (Pubitemid 36859944)
23. Patton MQ, Qualitative research and evaluation methods Thousand Oaks, London, New Delhi: Sage Publications 3 2002
24. Médecins Sans Frontières, No time to quit: HIV/AIDS treatment gap widening in Africa Brussels: Médecins Sans Frontières 2010
25. Paillé P, Mucchielli A, L'analyse qualitative en sciences humaines et sociales Paris: Colin 2003 22396904
26. Targeting services towards the poor: a review of targeting mechanisms and their effectiveness. Hanson K, Worrall E, Wiseman V, Health, economic development and household poverty: from understanding to action London: Routledge, Mills A, Bennett S, Gilson L, 2007 134 154
27. WHO, Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, September 2009 Geneva: World Health Organization 2009
28. Donor fatigue is slashing access to AIDS care in Africa, warns charity. Moszynski P, BMJ 2010 340 2844 10.1136/bmj.c2844 20508020
29. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. Geng E, Bangsberg D, Musinguzi N, Emenyonu N, Bwana M, Yiannoutsos C, et al. J Acquir Immune Defic Syndr 2010 53 405 411 10.1097/QAI.0b013e3181b843f0 19745753
30. Socio-demographic correlates of late treatment initiation in a cohort of patients starting antiretroviral treatment in Mali, West Africa. Pirkle CM, Nguyen V-K, Ag Aboubacrine S, Cissé M, Zunzunegui M-V, AIDS Care 2011 23 11 1425 1429 10.1080/09540121.2011.565026 22022850
31. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome. Wouters E, Van Damme W, Van Loon F, van Rensburg D, Meulemans H, Soc Sci Med 2009 69 8 1177 1185 10.1016/j.socscimed.2009.07.034 19692165
32. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, Chinji C, Humblet P, Harries AD, Trans R Soc Trop Med Hyg 2007 101 1 79 84 10.1016/j.trstmh.2006.05.010 16962622 (Pubitemid 44760916)
33. L'argent et l'entregent. Vuarin R, Cahier des sciences humaines 1994 30 1-2 255 271
34. Early antiretroviral therapy mortality in resource-limited settings: what can we do about it? Bekker LG, Egger M, Wood R, Curr Opin HIV AIDS 2007 2 4 346 351 10.1097/COH.0b013e3281e72cbd 19372910 (Pubitemid 46941830)
35. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Lancet 2006 367 9513 817 824 16530575
36. Antiretroviral globalism, biopolitics, and therapeutic citizenship. Nguyen V-K, Global assemblages: technology, politics, and ethics as anthropological problems Oxford: Blackwell Publishing, Ong A, Collier SJ, 2005
37. A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. Cantrell RA, Sinkala M, Megazinni K, Lawson-Marriott S, Washington S, Chi BH, Stringer JS, J Acquir Immune Defic Syndr 2008 49 2 190 195 10.1097/QAI.0b013e31818455d2 18769349
38. Accès au traitement antirétroviral: leçons des expériences. Kouanda S, Science et technique, Sciences de la santé, Spécial hors série n°1 2008 102 116
39. The cost of universal free access for treating HIV/AIDS in low income countries: the case of Senegal. Taverne B, Diop K, Vinard P, The political economy of HIV/AIDS in developing countries: TRIPS, public health systems and free access London: Edward Elgar, Coriat B, 2008 273 290
40. Public health implications of antiretroviral therapy and HIV drug resistance. Wainberg MA, Friedland G, JAMA 1998 279 24 1977 1983 10.1001/jama.279.24.1977 9643862 (Pubitemid 28298277)
41. High level of primary drug resistance in Mali. Haidara A, Chamberland A, Sylla M, Aboubacrine S, Cissé M, Traore H, ATARAO Group, HIV Med 2010 11 6 404 411 20146734
42. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. Tebit DM, Sangaré L, Tiba F, Saydou Y, Makamtse A, Somlare H, Bado G, Kouldiaty BG, Zabsonre I, Yameogo SL, Sathiandee K, Drabo JY, Krausslich HG, Medical Virology 2009 81 10 1691 1701 10.1002/jmv.21600
43. Munro K, Addressing adherence to antiretroviral therapy in Ouagadougou, Burkina Faso: insights from hospital ethnography (Unpublished master's thesis) Montreal, Quebec, Canada: University of Montreal 2009
44. Funding cuts spark fears about the rise of drug-resistant strains of HIV in Africa. Anonymous, CMAJ 2010 182 3 165 E166 10.1503/cmaj.109-3149 20064947